Compare MMSI & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MMSI | BLLN |
|---|---|---|
| Founded | 1987 | 2016 |
| Country | United States | United States |
| Employees | N/A | 713 |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.9B |
| IPO Year | 1996 | N/A |
| Metric | MMSI | BLLN |
|---|---|---|
| Price | $63.91 | $82.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 7 |
| Target Price | $98.88 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 792.2K | 609.5K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.93 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $1,515,906,000.00 | N/A |
| Revenue This Year | $8.85 | $46.29 |
| Revenue Next Year | $5.88 | $30.14 |
| P/E Ratio | $93.65 | ★ N/A |
| Revenue Growth | ★ 11.75 | N/A |
| 52 Week Low | $59.74 | $61.96 |
| 52 Week High | $99.26 | $138.70 |
| Indicator | MMSI | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 46.75 | 48.84 |
| Support Level | N/A | $79.33 |
| Resistance Level | $71.68 | $97.36 |
| Average True Range (ATR) | 2.55 | 8.35 |
| MACD | 0.31 | -0.33 |
| Stochastic Oscillator | 47.25 | 34.75 |
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.